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Symptomatic intracranial atherosclerotic disease (ICAD) is responsible for approximately 10% 
of all ischemic strokes in the United States.  The risk of recurrent stroke may be as high as 35% 
in patient with critical stenosis >70% in diameter narrowing. Recent advances in medical and 
endovascular therapy have placed ICAD at the forefront of clinical stroke research to optimize 
the best medical and endovascular approach to treat this important underlying stroke etiology. 
Analysis of symptomatic ICAD studies lead to the question that whether angioplasty and/or 
stenting is a safe, suitable, and efficacious therapeutic strategy in patients with critical stenoses 
that are deemed refractory to medical management. Most of the currently available data in 
support of angioplasty and/or stenting in high risk patients with severe symptomatic ICAD is 
in the form of case series and randomized trial results of endovascular therapy versus medical 
treatment are awaited.  This is a comprehensive review of the state of the art in the endovascular 
approach with angioplasty and/or stenting of symptomatic ICAD.
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  recurrent stroke in the symptomatic vascular territory at 1 year on 
aspirin or warfarin, respectively, and 17–20% at 2 years (Chimowitz 
et al., 2005). Patients with 70–99% stenosis had a recurrent stroke 
risk of 18% at 1 year compared to patients with 50–69% who had 
a 7% risk of stroke at 1 year (Kasner et al., 2006). Additionally, time 
from qualifying event (≤17 days) predicted risk of recurrent stroke 
(Kasner et al., 2006). Furthermore patients with intracranial stenosis 
who fail antithrombotic therapy were not at a higher risk for stroke 
than those who did not fail antithrombotic therapy (Turan et al., 
2009). All of these analyses lead to the question that in patients 
with symptomatic severe ICAD defined as ≥70% stenosis is angi-
oplasty and/or stenting a safe, effective, and viable treatment option? 
Currently, there is no data from a randomized controlled trial to 
guide clinicians toward an endovascular treatment of ICAD related 
ischemic strokes. Additionally there are no specific recommenda-
tions in the American Heart Association (AHA)/American Stroke 
Association (ASA) guidelines (Adams et al., 2008) for treatment or 
secondary prevention from ICAD related ischemic stroke. Most of 
the data currently available supporting angioplasty and stenting of 
ICAD is in the form of case series and there is no Level 1 evidence 
available to support endovascular therapy over medical manage-
ment. The ongoing stenting and aggressive medical management for 
preventing recurrent stroke in intracranial stenosis (SAMMPRIS) 
trial is a randomized controlled trial that should help determine if 
intracranial stenting is superior to best medical management for 
symptomatic ICAD of 70–99% (Derdeyn and Chimowitz, 2007).
The  endovascular  treatment  of  symptomatic  ICAD  has 
evolved  with  advances  in  technology.  Originally  balloons 
and stents designed for the coronary vasculature were used. 
IntroductIon
Symptomatic intracranial atherosclerotic disease (ICAD) is respon-
sible for approximately 10% of all ischemic strokes in the United 
States (Sacco et al., 1995; Qureshi et al., 2003). The prevalence of 
ICAD related ischemic stroke is higher in African American (17%) 
and Hispanics (13%) than among white Americans (9%); however, 
it is highest in the Chinese population (33–37%; Huang, 1997; 
Wong et al., 1998; White et al., 2005). Independent risk factors 
for ICAD are age, hypertension, and diabetes mellitus (Bae et al., 
2007). Total serum cholesterol, HDL, and LDL may also be a risk 
factors for developing ICAD (Kostner et al., 1986; Suwanwela et al., 
2006). Risk factors for recurrent ischemic stroke from ICAD include 
hypertension (systolic ≥ 140 mmHg), hyperlipidemia (≥200 mg/
dl), no alcohol consumption, and diabetes mellitus (Wong, 2003; 
Chaturvedi et al., 2007). Men may have a higher risk for developing 
ICAD particularly at younger ages (Passero et al., 1987; Moossy, 
1993), but women appear to have a higher recurrent risk (Kasner 
et  al.,  2006).  Angiotensin  converting  enzyme  polymorphisms, 
plasma endostatin/vascular endothelial growth factor ratio, glu-
tathione S-transferase omega-1 gene polymorphism, and plasma 
homocysteine levels are non-modifiable risk factors noted to be 
associated with ICAD. Sickle cell disease is an uncommon risk factor 
that can also be managed to reduce the risk of stroke. Associations 
of ICAD with diabetes mellitus, metabolic syndrome, Alzheimer’s 
disease, aortic plaques, radiotherapy, and meningitis are less well 
documented (Suri and Johnston, 2009).
In the comparison of warfarin and aspirin for symptomatic 
intracranial arterial stenosis (WASID) trial, patients with symp-
tomatic 50–99% intracranial stenosis had 12 and 11% risks of Frontiers in Neurology  |  Endovascular and Interventional Neurology    February 2011  | Volume 1  | Article 160  |  2
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stroke). Two patients had strokes in the territory of angioplasty at 
2 and 37 months after angioplasty. The annual stroke rate in the 
territory appropriate to the site of angioplasty was 3.4%, and for 
those patients with a residual stenosis of ≥50% it was 4.5%.
A Cochrane review of 79 articles (a total of 1999 cases) consist-
ing of open-label case series with three or more cases of primary 
angioplasty was published in 2006 (Cruz-Flores and Diamond, 
2006). The safety profile of the procedure showed an overall peri-
operative rate of stroke of 7.9%, perioperative death of 3.4%, and 
perioperative stroke or death of 9.5%. Of these studies with a 1-year 
follow-up the stroke rate at 1 year was 6%.
All these descriptive studies show that the procedure is feasi-
ble though it carries a significant morbidity and mortality risk. 
Technical disadvantages such as dissection of the artery, vessel 
occlusion, immediate elastic recoil, and higher restenosis rates cou-
pled with the vast amount of data from the coronary literature has 
rendered a somewhat inferior impression of balloon angioplasty 
alone compared to angioplasty with stenting; however, that being 
said the two modalities have not been compared head to head pro-
spectively. Evidence from randomized controlled trials is needed 
to assess the safety of primary angioplasty and its effectiveness in 
preventing recurrent stroke.
IntracranIal angIoplasty and stent placement
Currently data exists for three different categories of stents in the treat-
ment of ICAD: balloon expandable bare metal stents (BEBMS), drug-
eluting balloon expandable stents, and self-expanding stents. Stent 
systems can also be divided into those that are primarily designed for 
the coronary vasculature (Table 1) and those that have been specifi-
cally designed for the intracranial vasculature (Table 2).
Balloon expandaBle Bare metal stents
Primary angioplasty without stent placement was occasionally 
complicated by dissection, acute vessel closure, and embolization 
(Higashida et al., 1993; Terada et al., 1996; Callahan and Berger, 
1997; Takis et al., 1997; Volk et al., 1997; Conners and Wojak, 1999; 
Marks et al., 1999). Initially, BEBMS were used to an acute vessel 
dissection after angioplasty of a ICAD lesion; however, many of the 
coronary stents were rigid making them difficult to navigate into the 
intracranial circulation (Dorros et al., 1998). Several coronary stents 
were found to be sufficiently flexible to track into the intracranial 
circulation  including  the  Gianturco–Rubin-2  stent  (Phatouros 
et al., 1999), Palmaz–Schatz stent (Dorros et al., 1998), and the 
Arterial Vascular Engineering stent series which included the AVE 
S670stend and Guidant Tetramultilink stent (Morris et al., 1999; 
Phatouros et al., 1999).
Mori et al. (1999, 2000) treated 10 patients with 12 intracranial 
occlusive lesions with flexible BEBMS; however 2 lesions were not 
accessible. In six of eight vertebrobasilar and two distal internal 
carotid artery lesions GFX stents (Medtronics, Santa Rosa, CA, 
USA) were successfully deployed. Two distal internal carotid artery 
lesions were successfully stented with Multilink coronary stents 
(Guidant/Vascular Intervention, CA, USA). In the 10 lesions suc-
cessfully treated, a pre-stent stenosis of 80% was reduced to 7%. 
No periprocedural complications occurred and no ischemic events 
were reported in 11 months of follow-up. At 3 months all patients 
had follow-up angiograms which showed no restenosis.
Recently, stents designed specifically for the intracranial vas-
culature and the treatment of ICAD have been approved and 
are being used.
For the purpose of this review a literature search was performed 
using the keywords of intracranial angioplasty and/or stenting 
and cases series were identified in which either both or one of 
the modalities was used to treat symptomatic ICAD. We subse-
quently divided this review into categories based on the modality 
used either angioplasty and/or stenting and within the latter have 
reviewed the different stent types currently available.
endovascular treatment of Icad
prImary IntracranIal angIoplasty
Early studies with intracranial percutaneous transluminal angi-
oplasty (PTA) reported a high risk of intraprocedural vessel rup-
ture, vasospasm, dissection, or death in up to 33% of patients 
(Higashida et al., 1993; Terada et al., 1996; Callahan and Berger, 
1997; Takis et al., 1997; Volk et al., 1997; Conners and Wojak, 1999; 
Marks et al., 1999). Angioplasty for symptomatic intracranial ste-
nosis was first reported by Sundt et al. (1980). Subsequently several 
groups have reported successful PTA for ICAD defined as <50% 
residual  stenosis,  with  few  complications  in  retrospective  case 
series. Marks et al. (1999) reported 23 patients treated with PTA 
for symptomatic ICAD. Angioplasty resulted in reduced stenosis 
in 21 of 23 patients treated. In one patient, the lesion could not be 
crossed safely, and in the other patient balloon dilatations resulted 
in vessel rupture and death. During 3 years of follow-up the annual 
stroke rate was 3.2%. Conners and Wojak (1999) have also reported 
a 9-year retrospective analysis of PTA for ICAD related ischemic 
stroke. Slower balloon inflation combined with balloon under-
sizing resulted in reduced complications, but occasionally yielded 
suboptimal angiographic results. Oversized balloons with rapid 
inflation were used in 12 patients and 9 of those patients (75%) 
had angiographic dissections with 1 patient dying from a vessel 
occlusion. In comparison 50 patients were treated with undersized 
balloons and slower inflation times with a 14% risk of dissection 
all of which were asymptomatic.
Callahan and Berger (1997) treated 15 patients with ICAD 
related stroke who had failed warfarin therapy. Dilation was suc-
cessful in all vessels, with residual stenosis averaging <30%; how-
ever, one patient died secondary to vessel rupture and another 
suffered an ischemic stroke in the pons secondary to perforator 
compromise. Residual stenosis occurred in 16% with no stenosis 
measuring over 70%. Late restenosis occurred in 9% and were suc-
cessfully retreated. One guidewire perforation occurred resulting 
in the death of a patient. Nasher et al. (2000) reported 20 patients 
treated with PTA for vertebrobasilar stenosis. Success rate was 86% 
with complete resolution of posterior circulation symptoms. One 
patient had an ischemic stroke during the procedure. There was a 
14% rate of restenosis over 3–18 months.
A retrospective study was done to evaluate 36 patients with 
37 symptomatic atherosclerotic intracranial stenosis who under-
went primary balloon angioplasty after failing medical manage-
ment (Marks et al., 2005). Thirty-four patients were available for 
  follow-up at a mean of 53 months. The mean pretreatment stenosis 
was 84% before angioplasty and 43% after angioplasty. The peripro-
cedural death and stroke rate was 8.3% (two deaths and one minor www.frontiersin.org  February 2011  | Volume 1  | Article 160  |  3
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inferior cerebellar artery (PICA)] were treated. In the SSYLVIA 
study, the NEUROLINK System (Guidant Corporation) was used. 
It was specifically designed for navigating intracranial vasculature 
by having only a few links connect the rings, rendering the stent 
flexible enough to navigate tortuous intracranial vessels. In the first 
30 days, 6.6% had ischemic strokes and no deaths occurred. Of the 
55 intracranial lesions treated 33 had stenosis measuring 70–99% 
of which one patient had a stroke within the 30-day period. After 
30 days, 7.3% of patients had recurrent ischemic strokes. Successful 
stent placement was achieved in 95% of cases. At 6 months, rest-
enosis of ≥50% occurred in 32.4% intracranial arteries and 42.9% 
extracranial vertebral arteries. Thirty-nine percent of patients with 
recurrent  stenoses  were  symptomatic.  Post-procedure  stenosis 
>30%, parent vessel diameter, and diabetes mellitus were all fac-
tors linked to restenosis. The NEUROLINK system however was not 
marketed past the trial as Guidant disbanded its neurovascular unit. 
Nevertheless this trial provided valuable data about the safety of 
stenting in the treatment of ICAD. Different from the prior BEBMS 
the NEUROLINK had been specifically designed with the intracra-
nial vasculature in mind. Since its discontinuation there until very 
recently were no other BEBMS for ICAD. Micrus Corporation® 
(San Jose, CA, USA) most recently has designed the Pharos Vitesse 
Chrome Cobalt BEMS that is under study in Europe.
Gomez et al. (2000) treated 12 patients with symptomatic basilar 
artery stenosis with flexible BEBMS coronary stents (Microstent II 
or GFX, Advanced Vascular Engineering, Inc. or Multilink Duet, 
Guidant, Inc.). Stenosis was reduced from an average of 71–10%. 
There were no deaths, stent thromboses, perforations, ruptures, or 
myocardial infarctions. One patient had non-specific symptoms, 
and another had a transient ischemic attack at a mean follow-up 
of 5.9 months.
Mazighi et al. (2008) retrospectively reviewed 53 consecutive 
symptomatic patients with 69 intracranial arterial lesions who were 
treated with coronary BEBMS. The technical success rate was 98.6%, 
with a reduction of the median percent stenosis from 85 to 0%. 
Stents were placed in 76.8%. The 30-day death or stroke rate was 
10.1% with one death. With a median follow-up of 24 months, the 
transient ischemic attack or stroke rate reached 5.8%. The restenosis 
rate at 1 year was 15.9% and was symptomatic in two patients.
The stenting of symptomatic atherosclerotic lesion in the ver-
tebral or intracranial arteries (SSYLVIA) was a non-randomized, 
multicenter feasibility study that enrolled 61 patients with symp-
tomatic disease (SSYLVIA Study Investigators, 2004). Forty-three 
patients with intracranial arteries (15 internal carotid, 5 mid-
dle cerebral, 1 posterior cerebral, 17 basilar, 5 vertebral) and 18 
extracranial vertebral arteries [6 ostia, 12 proximal to the posterior 
Table 1 | Summary of coronary stent studies used for treatment of intracranial stenosis.
Study  Type  Subjects  30-day outcomes  Long-term outcomes  Restenosis rates
Mori et al. (2000)  Retrospective  10  No stroke or death  No ischemic events at 11 months  No restenosis at 3 months
Gomez et al. (2000)  Retrospective  12  No stroke or death  2 patients had a TIA at 6 months  2/12 had F/U, 1 had basilar 
          occlusion at 4 months
Mazighi et al. (2008)  Retrospective  53*  10% stroke or death  6% TIA or stroke at 2 years  16% at 1 year
Abou-Chebl et al. (2005)**  Retrospective  8  1 patient had TIA  No stroke or TIAs at 11 months  No restenosis at 10 months
Qureshi et al. (2006)**  Retrospective  18  1 stroke, no deaths  22% at 14 months  14% at 14 months
Gupta et al. (2006)**  Retrospective  26 of 29  12% stroke or  5% stroke at 4 months  5% at 4 months 
    attempted  dissection
Steinfort et al. (2007)**  Retrospective  13  8% stroke  8% stroke at 11 months  9/12 had F/U with 0% 
          at 5 months
Natarajan et al. (2010)***  Retrospective  6  17% stroke  0% at 4–10 months  0% at 6 months
*Only 76% of patients were treated with stents.
**Studies using drug-eluting stents.
***Second generation drug-eluting stent.
Table 2 | Symptomatic intracranial atherosclerosis studies using stents designed for intracranial use.
Study  Type  Subjects  30-day outcomes  Long-term outcomes  Restenosis rates
SSYLVIA (2004)  Prospective,   61  7% stroke, no deaths  7% after 30 days at 6 months  32% intracranial,  
  single arm        43% extracranial
Bose et al. (2007)  Prospective,   45  5% ipsilateral stroke/death  7% ipsilateral stroke or  3/40 patients studied had 
  single arm      death at 6 months  asymptomatic restenosis
Fiorella et al. (2007)  Prospective  78  6% stroke/death  Not reported  30%* at 6 months
    82 lesions     
Zaidat et al. (2008)  Registry  129  10% stroke/death  14% stroke/death at 30 days or  25% at 5 months 
        ipsilateral stroke at 6 months
*Reported by Levy et al., (2007).Frontiers in Neurology  |  Endovascular and Interventional Neurology    February 2011  | Volume 1  | Article 160  |  4
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symptomatic ICAD who had ≥50% stenosis where included. The 
Wingspan stent system was used in all patients and consists of self-
expanding nitinol stent preloaded in a delivery catheter and a sepa-
rately packaged Gateway PTA balloon catheter (Boston Scientific 
Corp; Figure 1). The 30-day composite ipsilateral stroke or death 
rate was 4.5%, and 7% at 6 months. The degree of stenosis was 
reduced from an average of 75–32%. Three patients had restenosis 
of ≥50% but were not symptomatic. There were no procedural in-
stent thromboses or parent vessel dissections or perforations.
Subsequently the real life experience of this system has been 
recorded  in  two  prospective  registries.  In  the  US  Multicenter 
Experience with the Wingspan Stent System for the Treatment of 
Intracranial Atheromatous Disease all patients undergoing angi-
oplasty and stenting using the Gateway balloon–Wingspan stent 
system were prospectively followed (Fiorella et al., 2007). During 
a 9-month period, treatment with the Wingspan stent system was 
attempted in 78 patients with 82 intracranial atheromatous lesions, 
of which 54 were ≥70% stenotic. Eighty-one of 82 lesions were suc-
cessfully stented (98.8%) during the first treatment session with 
the other treated only with angioplasty and stented at a later date. 
The mean pretreatment stenosis was 74.6%, improving to 43.5% 
after balloon angioplasty and to 27.2% after stent placement. There 
were five (6.1%) major periprocedural neurological complications, 
four of which ultimately led to patient death within 30 days of the 
procedure. Diffusion-weighted MRI sequences were done on 38 
patients within 72 h of the procedure. Thirteen (34.2%) had new 
ischemic lesions with only three being symptomatic.
In the NIH Registry on the use of the Wingspan Stent for 
Symptomatic 70–99% Intracranial arterial stenosis 129 consecutive 
patients were enrolled (Zaidat et al., 2008). The technical success 
rate was 96.7%. The mean pre-stent stenosis was 82% reduced 
to 20% after stenting. The frequency of any stroke, intracerebral 
hemorrhage, or death within 30 days or ipsilateral stroke beyond 
30 days was 14% at 6 months. Any stroke or death occurred in eight 
patients (6.2%) within 24 h of treatment. Fifty-two patients (40%) 
had follow-up cerebral angiograms at a mean of 4.8 months. The 
mean residual stenosis was 29%, with 13 patients (25%) having 
restenosis ≥50%, and 2 patients had ischemic stokes with both 
attributed to stent occlusions.
The Wingspan SEIS is currently under study in SAMMPRIS to 
compare stenting with aggressive medical management.
comparIson of BeBms/des to seIs
Gröschel et al. (2009) conducted a systematic review 31 studies 
dealing  with  1177  intracranial  stenting  procedures  from  1998 
to 2008. Ninety-eight percent were performed in patients with a 
drug-elutIng stents
Some investigators have employed the use of drug-eluting stents 
(DES) to treat ICAD as have been used in the coronary vascula-
ture. DES have a coating of antiproliferative material that inhibits 
neointimal hyperplasia. Steinfort et al. (2007) reported a review of 
13 patients with symptomatic posterior circulation stenosis treated 
with pacilitaxel-coated stents. One patient suffered a periprocedural 
stroke, and nine patients had angiographic follow-up at a mean of 
5.4 months with no significant in-stent stenosis. Qureshi et al. (2006) 
treated 18 patients with either a sirolimus-eluting stent (n = 14) or 
a paclitaxel-eluting stent (n = 4) for symptomatic stenosis (≥70% 
or failed medical management). There was one major stroke and 
no death observed in the 1-month follow-up. Major stroke-free 
survival was 86% at 12 months. One symptomatic angiographic 
restenosis was observed during the follow-up period. Abou-Chebl 
et al. (2005) reviewed eight patients treated with DES with >70% 
stenoses that had failed maximal medical therapy. Patients were 
pretreated with aspirin and clopidogrel and these were contin-
ued after the procedure for 1 year. Eight patients with intracranial 
lesions: internal carotid artery (3), middle cerebral (2), basilar (2), 
and vertebral artery (1) stenoses were successfully treated with 4 
Cypher (Cordis Corp) and 4 Taxus (Boston Scientific) stents. The 
mean stenosis severity was reduced from 84.4 to 2.5%. One patient 
had an intraprocedural retinal embolism, but there were no other 
complications. Over a mean follow-up of 11 months, patients had 
repeat angiography (5) or transcranial Doppler with or without 
CT angiography (3). None of the patients had clinical or signifi-
cant angiographic restenosis. Likewise, Gupta et al. (2006) showed 
feasibility and safety by treating 62 symptomatic lesions, of which 
26 were ICAD, with DES (Cypher or Taxus). Intracranial stent-
ing was attempted in 29 but only successfully deployed in 26. At 
angiographic follow-up, 1 of 26 (5%) intracranial DES and 2 of 36 
extracranial DES were found to have restenosis ≥50% at a mean 
  follow-up of 4 months. The previous DES studies used first gen-
eration stents with sirolimus or paclitaxel. Natarajan et al. (2010) 
reported six patients with symptomatic ICAD treated with a sec-
ond generation DES that has greater deliverability. The Xience V 
everolimus-eluting stent (Abbott Vascular) was placed in six patients 
with >70% stenosis. Average stenosis was reduced from 83 to 6%. 
There was one post-intervention hemorrhage which required a 
craniectomy. Five of six patients had angiographic follow-up at 
5–6 months with no restenosis.
There is still insufficient data to recommend the safe and effec-
tive use of DES in the intracranial vasculature and more study is 
required. The ongoing concerns with DES is the need for prolonged 
use of dual antiplatelet therapy with aspirin and clopidrogel which 
may increase the risk of hemorrhage especially in the brain and 
late restenosis.
self-expandIng IntracranIal stents
The Wingspan stent system® (Boston Scientific) was the first self-
expanding intracranial stents (SEIS) to be approved for the treat-
ment of ICAD in patients with medically refractory disease under 
a humanitarian device exemption (HDE) in August 2005. This was 
approved after being studied in a prospective, multicenter, single-
arm intracranial stenting study for medically refractory patients 
in Europe and Asia (Bose et al., 2007). Forty-five patients with 
FiGuRe 1 | Right middle cerebral artery stenosis treated with SeiS/
Wingspan stent.www.frontiersin.org  February 2011  | Volume 1  | Article 160  |  5
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  comparable to the NIH Wingspan registry (Zaidat et al., 2008; 
25%). Typically ISR is asymptomatic (76%) but it can cause neu-
rological symptoms (Levy et al., 2007). Thirty-six patients in the 
registry experienced in ISR after PTA and stenting with Wingspan. 
Of these patients, 29 (80.6%) have undergone target lesion revas-
cularization with either angioplasty alone (n = 26) or angioplasty 
with restenting (n = 3). Restenting was performed for in-stent 
dissections that occurred after the initial angioplasty. Of the 29 
patients undergoing target lesion revascularization, 9 required ≥ 1 
interventions for recurrent ISR, for a total of 42 interventions. One 
major complication, a post-procedural reperfusion hemorrhage, 
was encountered in the periprocedural period (2.4% per proce-
dure; 3.5% per patient). Angiographic follow-up was available for 
22 of 29 patients after target lesion revascularization. Eleven of 22 
(50%) demonstrated recurrent ISR at follow-up angiography. Nine 
patients had multiple retreatments for recurrence. Recurrent lesions 
were more common in the anterior circulation.
In-stent restenosis in most instances is asymptomatic and 
therefore its management and the need for retreatment with 
angioplasty and/or stenting is not clear. However most operators 
feel the need to retreat if the ISR causes a stenosis that is worse 
than the original lesion or the patient becomes symptomatic. 
Further study is required to identify patients at risk, potentially 
modifiable risk factors and methods of treatment of ISR after 
stenting of ICAD.
medIcal management compared to endovascular treatment
Patients from the WASID trial (254) and from the NIH Wingspan 
multicenter stent registry (158) were matched to determine the 
differential rate of stroke or death within 30 days or ipsilateral 
stroke beyond 30 days (Jarvis et al., 2008). They were divided into 
two categories of 50–69% and 70–99% stenosis. The primary event 
rates in WASID patients with 70–99% stenosis was 7 and 16%, 
respectively; the comparable rates in the Wingspan group were 
10 and 13%. There was no difference in the 50–69% groups. As 
mentioned previously, SAMMPRIS is an ongoing trial comparing 
stenting combined with best medical management to best medical 
management alone.
prImary angIoplasty compared to angIoplasty wIth stent 
placement
Siddiq et al. (2008) retrospectively analyzed the clinical and angi-
ographic data of 190 patients treated with 95 primary angioplasty 
procedures and 98 intracranial stent placements in three tertiary 
care centers. Fourteen procedures in the angioplasty-treated group 
(15%) and four in the stent-treated group (4%) had significant 
post-operative residual stenosis. There were 3 periprocedural deaths 
(1.5%), 1 in the angioplasty group (1%) and 2 in the stent-treated 
group (2.0%) and 14 periprocedural strokes (7.3%), 7 periproce-
dural strokes in each group (7.4 and 7.1%). Angiographic follow-up 
was available for 134 procedures (66 angioplasty-treated and 68 
stent-treated cases). Forty-eight patients had restenosis (25 of 66 
angioplasties, 23 of 68 stents). Restenosis-free survival at 12 months 
was 68% for the angioplasty-treated group and 64% for the stent-
treated group. There was no difference in follow-up survival (stroke, 
or stroke and/or death) between the angioplasty-treated and the 
stent-treated groups at 2 years.
  symptomatic high-grade (mean: 78%) intracranial stenosis. The 
median technical success rate was 96%. The periprocedural minor 
or major stroke and death rates ranged from 0 to 50% with a median 
of 7.7%. Periprocedural complications were significantly higher in 
the posterior (12.1%) versus the anterior circulation (6.6%), but 
did not differ between patients treated with a balloon-mounted 
versus those who had been treated with a self-expandable stent(s). 
However restenosis ≥50% occurred more frequently after the use of 
a self-expandable stent (17.4%, mean follow-up of 5.4 months) than 
a balloon-mounted stent (13.8%, mean follow-up of 8.7 months). 
This has been attributed to the higher amount of radial force 
applied to the vessel by BEBMS and that most SEIS are deployed 
after a submaximal angioplasty.
A comparison of stent design between coronary and cerebral 
stents can be seen in Figure 1.
restenosIs after angIoplasty and stentIng
Albuquerque et al. (2008) described in-stent restenosis (ISR) as 
>50% stenosis within or immediately adjacent (within 5 mm) to 
the implanted stent(s) and >20% absolute luminal loss. Imaging 
  follow-up (3–15.5 months) was available for 127 intracranial stenotic 
lesions treated with the Wingspan stent system. Forty-one lesions 
(32%) developed either ISR (28%) or complete stent occlusion (4%) 
after treatment. When restenotic lesions were characterized using the 
modified classification system, 25 of 41 (61.0%) were focal lesions 
involving <50% of the length of the stented segment: three were Type 
IA (focal stenosis involving one end of the stent), 21 were Type IB 
(focal intrastent stenosis involving a segment completely contained 
within the stent), and one was Type IC (multiple non-contiguous 
focal stenoses). Eleven lesions (26.8%) demonstrated diffuse stenosis 
(>50% of the length of the stented segment): nine were Type II with 
diffuse intrastent stenosis (completely contained within the stent) 
and two were Type III with proliferative in-stent stenosis (extending 
beyond the stented segment). Five stents were completely occluded 
at follow-up (Type IV). Of the 36 ISR lesions, 16 were less severe or 
no worse than the original lesion with respect to severity of stenosis 
or length of the segment involved. Twenty lesions were more severe 
than the original lesion. Supraclinoid internal carotid artery and 
middle cerebral artery lesions have a propensity to develop more 
severe post-treatment stenosis.
Levy et al. (2007) reported follow-up imaging (average duration, 
5.9 months) available for 84 lesions treated with the Wingspan 
stent (78 patients). Follow-up examinations consisted of 65 con-
ventional angiograms, 17 computed tomographic angiograms, and 
two magnetic resonance angiograms. ISR was documented in 25 
and complete thrombosis in 4 patients. Two of the four patients 
with stent thrombosis had lengthy lesions requiring more than 
one stent to bridge the diseased segment. ISR was more frequent 
in the anterior circulation (42%) than the posterior circulation 
(13%). Eight patients were symptomatic (four with stroke, four 
with transient ischemic attack) and 15 were retreated. Of these, 
four were complicated by clinically silent in-stent dissections, two 
of which required the placement of a second stent. One patient had 
a post-procedural reperfusion hemorrhage.
The ISR rate with the Wingspan stent is higher in the multi-
center experience Levy and colleagues (Fiorella et al., 2007; 30%) 
than in the original Wingspan study (Bose et al., 2007; 15%), but Frontiers in Neurology  |  Endovascular and Interventional Neurology    February 2011  | Volume 1  | Article 160  |  6
Short et al.  Endovascular treatment of intracranial atherosclerotic disease
transient ischemic attack. Stroke 39, 
1647–1652.
Albuquerque, F. C., Levy, E. I., Turk, A. S., 
Niemann, D. B., Aagaard-Kienitz, B., 
Pride, G. L. Jr., Purdy, P. D., Welch, B. G., 
Woo, H. H., Rasmussen, P. A., Hopkins, 
L. N., Masaryk, T. J., McDougall, C. G., 
and Fiorella, D. J. (2008). Angiographic 
patterns of Wingspan in-stent resteno-
sis. Neurosurgery 63, 23–28.
Bae, H. J., Lee, J., Park, J. M., Kwon, O., 
Koo, J. S., Kim, B. K., and Pandey, D. 
K. (2007). Risk factors of intracra-
nial cerebral atherosclerosis among 
asymptomatics. Cerebrovasc. Dis. 24, 
355–360.
references
Abou-Chebl, A., Bashir, Q., and Yadav, J. 
S. (2005). Drug-eluting stents for the 
treatment of intracranial atheroscle-
rosis: initial experience and midterm 
angiographic follow-up. Stroke 36, 
e165–e168.
Adams, R. J., Albers, G., Alberts, M. J., 
Benavente, O., Furie, K., Goldstein, L. 
B., Gorelick, P., Halperin, J., Harbaugh, 
R., Johnston, S. C., Katzan, I., Kelly-
Hayes, M., Kenton, E. J., Marks, M., 
Sacco, R. L., and Schwamm, L. H. 
(2008). Update to the AHA/ASA 
recommendations for the prevention 
of stroke in patients with stroke and 
Bertrand, M. E., Rupprecht, H. J., Urban, 
P., and Gershlick, A. H. (2000). Double-
blind study of the safety of clopidogrel 
with and without a loading dose in 
combination with aspirin compared 
with ticlopidine in combination with 
aspirin after coronary stenting: the 
clopidogrel aspirin stent interna-
tional cooperative study (CLASSICS). 
Circulation 102, 624–629.
Bose, A., Hartmann, M., Henkes, H., Liu, 
H. M., Teng, M. M., Szikora, I., Berlis, 
A., Reul, J., Yu, S. C., Forsting, M., Lui, 
M., Lim, W., and Sit, S. P. (2007). A 
novel, self-expanding, nitinol stent 
in medically refractory intracranial 
atherosclerotic stenosis: the Wingspan 
study. Stroke 38, 1531–1537.
Callahan, A. S., and Berger, B. L. (1997). 
Balloon angioplasty of intracranial 
arteries for stroke prevention. J. 
Neuroimaging 7, 232–235.
Chaturvedi, S., Turan, T. N., Lynn, M. J., 
Kasner, S. E., Romano, J., Cotsonis, 
G., Frankel, M., and Chimowitz, M. I. 
(2007). Risk factor status and vascular 
events in patients with symptomatic 
intracranial stenosis. Neurology 69, 
2063–2068.
Chimowitz, M. I., Lynn, M. J., Howlett-
Smith, H., Stern, B. J., Hertzberg, 
V. S., Frankel, M. R., Levine, S. R., 
For these reasons endovascular therapy of symptomatic ICAD 
is best adopted through a multidisciplinary approach with stroke 
neurology, neuroradiology, neurosurgery, and neurointerventional-
ists. Careful patient selection is important paying special attention 
to the risk of hemorrhagic and thromboembolic complications 
that maybe encountered. Post-procedural neurointensive care and 
astute nursing care are paramount to help recognize these potential 
complications in a timely fashion.
In the absence of randomized data we cannot make a strong 
argument for angioplasty and stenting but it is an option that is 
available to patients in whom medical risk factors have already 
been maximally controlled and continue to have ongoing ischemic 
symptoms. Stenting appears to be more durable than angioplasty 
alone as we have discussed during this review however host factors 
such as difficult anatomy, vessel tortuosity, heavily calcified lesions, 
and the safety or tolerability of prolonged antiplatelet therapy may 
preclude stent placement and in our experience angioplasty alone 
is still an option in those scenarios.
Amongst the types of stents there is no randomized data compar-
ing BMS to SEIS. The initial excitement with SEIS has been quelled 
by restenosis rates however on the other hand the trackability and 
deliverability of BMS seems to be inferior to that of SEIS.
conclusIon
Technological advances over the last decade have made intracranial 
angioplasty and stenting a possible therapeutic option for patients 
with severe symptomatic ICAD. However at this point there is lack 
of evidence for its long-term efficacy when compared to medical 
therapy. Results of randomized trials comparing stenting to medical 
therapy are much awaited to see if endovascular management will 
have a more concrete role in the secondary prevention of stroke.
perIprocedural management
Based on the coronary intervention literature, practitioners are 
continuing dual antiplatelet agents for a total of 3 months after 
intracranial stent placement, although the range is 4–12 weeks 
(Schleinitz et al., 2004). Clopidogrel 75 mg daily with aspirin (81 
or 325 mg) for at least 72 h before the intervention is recommended. 
If not possible, a loading dose of clopidogrel 300 mg within 6–24 h 
or 600 mg within 6 h is reasonable (Bertrand et al., 2000). In patients 
allergic to clopidogrel, ticlopidine 250 mg daily or a 500-mg loading 
dose is a reasonable alternative (Levy et al., 2007). DES for coronary 
intervention require 1 year of dual antiplatelet therapy (Schleinitz 
et al., 2004), which is also reasonable for DES in the cerebral vascu-
lature (Qureshi et al., 2009). Additionally a very important factor 
is that stenting should not be a substitute for aggressive risk factor 
control and continued attention to control all modifiable risk fac-
tors needs to be paid. This should include aggressive blood pres-
sure, diabetes, and dyslipidemia management per stroke guidelines 
(Adams et al., 2008).
Complications to be considered around the time of angioplasty 
and stenting can be of varying severity (Jiang et al., 2007; Samaniego 
et al., 2009). Dangerous life threatening complications with severe 
morbidity and mortality are mainly from the risk of dissection 
and rupture of the parent vessel. Acute stent thrombosis can lead 
to occlusion of the stent and vessel predisposing to a malignant 
infarct and edema within the vessels vascular territory and usu-
ally occurs within a setting of suboptimal antiplatelet therapy. 
Furthermore acute to subacute revascularization with stenting 
after stroke can predispose to secondary hemorrhage within the 
ischemic bed.
When stenting is undertaken in perforator rich arteries there is 
a risk of the “snow plow” effect of pushing atheroma into the ostia 
of perforators and consequently causing a perforator stroke (PS; 
Figure 2). In a study by Jiang et al. (2006) using BMS a 3% PS rate 
was identified. The presence of preprocedural PS was associated 
with a higher likelihood of developing a new PS. This is in contrast 
to a study by Leung et al. (2009) which using SEIS (Wingspan™) 
had a 0% PS rate by MRI imaging over a 4-month period. It is 
felt that the submaximal <80% angioplasty used with SEIS is less 
likely to push plaque into perforators. However there are concerns 
with the continued outward radial force exerted by SEIS may cause 
more neointimal hyperplasia and restenosis which ultimately may 
cause delayed PSs.
FiGuRe 2 | Basilar stenosis treated with DeS. Note absent perforator/side 
branches post-stenting.www.frontiersin.org  February 2011  | Volume 1  | Article 160  |  7
Short et al.  Endovascular treatment of intracranial atherosclerotic disease
determinants in patients with symp-
tomatic vertebrobasilar stenosis: a 
multicenter study. Neurosurgery 52, 
1033–1039; discussion 1039–1040.
Sacco, R. L., Kargman, D. E., Gu, Q., 
and Zamanillo, M. C. (1995). Race-
ethnicity  and  determinants  of 
intracranial atherosclerotic cerebral 
infarction: the Northern Manhattan 
stroke study. Stroke 27, 1974–1980.
Samaniego,  E.  A.,  Hetzel,  S., 
Thirunarayanan, S., Aagaard-Kienitz, 
B., Turk, A. S., and Levine, R. (2009). 
Outcome of symptomatic intracra-
nial atherosclerotic disease. Stroke 40, 
2983–2987.
Schleinitz,  M.  D.,  Olkin,  I.,  and 
Heidenreich, P. A. (2004). Cilostazol, 
clopidogrel or ticlopidine to prevent 
sub-acute stent thrombosis: a meta-
analysis of randomized trials. Am. 
Heart J. 148, 990–997.
Siddiq, F., Vazquez, G., Memon, M. Z., 
Suri, M. F., Taylor, R. A., Wojak, J. 
C., Chaloupka, J. C., and Qureshi, 
A. I. (2008). Comparison of primary 
angioplasty with stent placement for 
treating symptomatic intracranial 
atherosclerotic disease: a multicenter 
study. Stroke 39, 2505–2510.
SSYLVIA Study Investigators. (2004). 
Stenting of symptomatic athero-
sclerotic lesions in the vertebral or 
intracranial arteries (SSYLVIA): study 
results. Stroke 35, 1388–1392.
Steinfort, B., Ng, P. P., Faulder, K., 
Harrington, T., Grinnell, V., Sorby, W., 
and Morgan, M. K. (2007). Midterm 
outcomes of   paclitaxel-eluting stents 
for the treatment of intracranial poste-
rior circulation stenosis. J. Neurosurg. 
106, 222–225.
Sundt, T. M., Jr, Smith, H. C., Campbell, 
J. K., Vlietstra, R. E., Cucchiara, 
R. F., Stanson, and A. W. (1980). 
Transluminal angioplasty for basilar 
artery stenosis. Mayo Clin. Proc. 55, 
673–680.
Suri, F. K. M., and Johnston, C. S. (2009). 
Epidemiology of intracranial stenosis. 
J. Neuroimaging 19, 11S–16S.
Suwanwela, N. C., Chutinet, A., and 
Phanthumchinda,  K.  (2006). 
Inflammatory markers and conven-
tional atherosclerotic risk factors in 
acute ischemic stroke:   comparative 
study  between  vascular  disease 
subtypes. J. Med. Assoc. Thai. 89, 
2021–2027.
Takis, C., Kwan, E. S., Pessin, M. S., Jacobs, 
D. H., and Caplan, L. R. (1997). 
Intracranial angioplasty: experience 
and complications. Am. J. Neuroradiol. 
18, 1661–1668.
Terada, T., Higashida, R. T., Halbach, 
V. V., Dowd, C. F., Nakai, E., Yokote, 
H., Itakura, T., and Hieshima, G. B. 
(1996). Transluminal angioplasty for 
race, and gender. Stroke 24, I22–I23, 
I31–I32.
Mori, T., Kazita, K., Chokyu, K., Mima, 
T., and Mori, K. (2000). Short-term 
arteriographic and clinical outcome 
after cerebral angioplasty and stent-
ing for intracranial vertebrobasilar and 
carotid atherosclerotic occlusive dis-
ease. Am. J. Neuroradiol. 21, 249–254.
Mori, T., Kazita, K., Seike, M., Nojima, 
Y., and Mori, K. (1999). Successful 
cerebral artery stent placement for 
total occlusion of the vertebrobasilar 
artery in a patient suffering from acute 
stroke. Case report. J. Neurosurg. 90, 
955–958.
Morris, P. P., Martin, E. M., Regen, J., 
and Braden, G. (1999). Intracranial 
deployment of coronary stents for 
symptomatic atherosclerotic disease. 
Am. J. Neuroradiol. 20, 1688–1694.
Nasher, H. C., Henkes, H., Weber, W., 
Berg-Dammer, E., Yousry, T. A., and 
Kühne, D. (2000). Intracranial verte-
brobasilar stenosis: angioplasty and 
follow-up. Am. J. Neuroradiol. 21, 
1293–1301.
Natarajan, S. K., Ogilvy, C. S., Hopkins, 
L. N., AH Siddiqui, EI Levy. (2010). 
Initial experience with an everolimus-
eluting, second generation drug-elut-
ing stent for treatment of intracranial 
atherosclerosis. J. Neurointerv. Surg. 
2, 104–109.
Passero, S., Rossi, G.,  Nardini,  M., 
Bonelli, G., D’Ettorre, M., Martini, 
A., Battistini, N., Albanese, V., Bono, 
G., and Brambilla, G. L. (1987). Italian 
multicenter study of reversible cer-
ebral ischemic attacks. Part 5. Risk 
factors and cerebral atherosclerosis. 
Atherosclerosis 63, 211–224.
Phatouros, C. C., Higashida, R. T., Malek, 
A. M., Smith, W. S., Mully, T. W., 
DeArmond, S. J., Dowd, C. F., and 
Halbach, V. V. (1999). Endovascular 
stenting of an acutely thrombosed 
basilar artery: technical case report and 
review of the literature. Neurosurgery 
44, 667–673.
Qureshi, A. I., Feldmann, E., Gomez, C. 
R., Johnston, S. C., Kasner, S. E., Quick, 
D. C., Rasmussen, P. A., Suri, M. F., 
Taylor, R. A., and Zaidat, O. O. (2009). 
Intracranial atherosclerotic disease: an 
update. Ann. Neurol. 66, 730–738.
Qureshi, A. I., Kirmani, J. F., Hussein, 
H. M., Harris-Lane, P., Divani, A. A., 
Suri, M. F., Janjua, N., and Alkawi, A. 
(2006). Early and   intermediate-term 
outcome with drug-eluting stents in 
high risk patients with symptomatic 
intracranial stenosis. Neurosurgery 5, 
1044–1051.
Qureshi, A. I., Ziai, W. C., Yahia, A. M., 
Mohammad, Y., Sen, S., Agarwal, P., 
Zaidat, O. O., Suarez, J. I., and Wityk, 
R. J. (2003). Stroke-free survival and its 
group. Outcome of patients with 
50–99% intracranial stenosis and 
TIA or stroke on antithrombotic 
therapy treated medically vs. stent-
ing. Presented at the 60th Annual 
Meeting of the American Academy of 
Neurology, Chicago, IL.
Jiang, W. J., Du, B., Leung, T. W., Xu, X. 
T., Jin, M., and Dong, K. H. (2007). 
Symptomatic intracranial stenosis: 
cerebrovascular complications from 
elective stent placement. Radiology 
243, 188–197.
Jiang, W. J., Srivastava, T., Gao, F., Du, 
B., Dong, K. H., and Xu, X. T. (2006). 
Perforator stroke after elective stenting 
of symptomatic intracranial stenosis. 
Neurology 66, 1868–1872.
Kasner, S. E., Chimowitz, M. I., Lynn, 
M. J., Howlett-Smith, H., Stern, B. J., 
Hertzberg, V. S., Frankel, M. R., Levine, 
S. R., Chaturvedi, S., Benesch, C. G., 
Sila, C. A., Jovin, T. G., Romano, J. G., 
and Cloft, H. J. (2006). Predictors of 
ischemic stroke in the territory of a 
symptomatic intracranial arterial ste-
nosis. Circulation 113, 555–563.
Kostner, G. M., Marth, E., Pfeiffer, K. P., 
and Wege, H. (1986). Apolipoproteins 
AI, AII and HDL phospholipids but 
not APO-B are risk indicators for 
occlusive cerebrovascular disease. Eur. 
Neurol. 25, 346–354.
Leung, T. W., Yu, S. C., Lam, W. W., Chan, 
A. Y., Lau, A. Y., and Wong, L. K. (2009). 
Would self-expanding stent occlude 
middle cerebral artery perforators? 
Stroke 40, 1910–1912.
Levy, E. I., Turk, A. S., Albuquerque, F. C., 
Niemann, D. B., Aagaard-Kienitz, B., 
Pride, L., Purdy, P., Welch, B., Woo, 
H., Rasmussen, P. A., Hopkins, L. 
N., Masaryk, T. J., McDougall, C. G., 
and Fiorella, D. J. (2007). Wingspan 
in-stent restenosis and thrombo-
sis: incidence, clinical presentation, 
and management. Neurosurgery 61, 
644–651.
Marks, M. P., Marcellus, M., Norbash, 
A. M., Steinberg, G. K., Tong, D., and 
Albers, G. W. (1999). Outcome of angi-
oplasty for atherosclerotic intracranial 
stenosis. Stroke 30, 1065–1069.
Marks, M. P., Marcellus, M. L., Do, H. M., 
Schraedley-Desmond, P. K., Steinberg, 
G. K., Tong, D. C., and Albers, G. W. 
(2005). Intracranial angioplasty with-
out stenting for symptomatic intrac-
ranial atherosclertotic stenosis: long 
term follow-up. Am. J. Neuroradiol. 
3, 525–530.
Mazighi, M., Yadav, J. S., and Abou-Chebl, 
A. (2008). Durability of endovascu-
lar therapy for symptomatic intrac-
ranial atherosclerosis. Stroke 39, 
1766–1769.
Moossy, J. (1993). Pathology of cerebral 
atherosclerosis. Influence of age, 
Chaturvedi, S., Kasner, S. E., Benesch, 
C. G., Sila, C. A., Jovin, T. G., and 
Romano, J. G. (2005). Comparison of 
warfarin and aspirin for symptomatic 
intracranial arterial stenosis. N. Engl. 
J. Med. 352, 1305–1316.
Conners, J. J., and Wojak, J. C. (1999). 
Percutaneous transluminal angi-
oplasty for intracranial atheroscle-
rotic lesions: evolution of technique 
and short-term results. J. Neurosurg. 
91, 415–423.
Cruz-Flores, S., and Diamond, A. L. 
(2006). Angioplasty for intracranial 
artery stenosis. Cochrane Database 
Syst. Rev. 3, CD004133.
Derdeyn, C. P., and Chimowitz, M. I. 
(2007). Angioplasty and stenting for 
atherosclerotic intracranial stenosis: 
rationale for a randomized clinical 
trial. Neuroimaging Clin. N. Am. 17, 
355–363.
Dorros, G., Cohn, J. M., and Palmer, L. 
E. (1998). Stent deployment resolves 
a petrous carotid artery angioplasty 
dissection. Am. J. Neuroradiol. 19, 
392–394.
Fiorella, D., Levy, E. I., Turk, A. S., 
Albuquerque, F. C., Niemann, D. B., 
Aagaard-Kienitz, B., Hanel, R. A., Woo, 
H., Rasmussen, P. A., Hopkins, L. N., 
Masaryk, T. J., and McDougall, C. G. 
(2007). US multicenter experience 
with the Wingspan stent system for 
the treatment of intracranial athero-
matous disease: periprocedural results. 
Stroke 38, 881–887.
Gomez, C. R., Misra, V. K., Liu, M. 
W., Wadlington, V. R., Terry, J. B., 
Tulyapronchote, R., and Campbell, 
M. S. (2000). Elective stenting of 
symptomatic basilar artery stenosis. 
Stroke 31, 95–99.
Gröschel, K., Schnaudigel, S., Pilgram, S. 
M., Wasser, K., and Kastrup, A. (2009). 
A systematic review on outcome after 
stenting for intracranial atherosclero-
sis. Stroke 5, e340–e347.
Gupta, R., Al-Ali, F., Thomas, A. J., 
Horowitz, M. B., Barrow, T., Vora, N. A., 
Uchino, K., Hammer, M. D., Wechsler, 
L. R., and Jovin, T. G. (2006). Safety, 
feasibility, and short-term follow-up 
of drug-eluting stent placement in the 
intracranial and extracranial circula-
tion. Stroke 37, 2562–2566.
Higashida, R. T., Tsai, F. Y., Halbach, V. 
V., Dowd, C. F., and Hieshima, G. B. 
(1993). Cerebral percutaneous trans-
luminal angioplasty. Heart Dis. Stroke 
2, 497–740.
Huang, Y. (1997). Vascular lesions in 
Chinese  patients  with  transient 
ischemic  attacks.  Neurology  48, 
524–525.
Jarvis, A. L., Chimowitz, M., and Lynn, 
M.  J.  (2008).  NIH  multicenter 
Wingspan intracranial stent study Frontiers in Neurology  |  Endovascular and Interventional Neurology    February 2011  | Volume 1  | Article 160  |  8
Short et al.  Endovascular treatment of intracranial atherosclerotic disease
arteriosclerotic disease of the distal 
vertebral and basilar arteries. J. Neurol. 
Neurosurg. Psychiatry 60, 377–381.
Turan, T. N., Maidan, L., Cotsonis, G., Lynn, 
M. J., Romano, J. G., Levine, S. R., and 
Chimowitz, M. I. (2009). Failure of anti-
thrombotic therapy and risk of stroke in 
patients with symptomatic intracranial 
stenosis. Stroke 40, 505–509.
Volk, E. E., Prayson, R. A., and Perl, J. 
(1997). Autopsy finding of fatal com-
plications of posterior cerebral circu-
lation angioplasty. Arch. Pathol. Lab. 
Med. 121, 738–740.
White, H., Boden-Albala, B., Wang, C., 
Elkind, M. S., Rundek, T., Wright, C. B., 
and Sacco, R. L. (2005). Ischemic stroke 
subtype incidence among whites, 
blacks, and Hispanics: the Northern 
Manhattan Study. Circulation 111, 
1327–1331.
Wong, K. S. (2003). Long-term mortal-
ity and recurrent stroke risks among 
Chinese stroke patients with pre-
dominant intracranial atherosclerosis. 
Stroke 34, 2361–2366.
Wong, K. S., Huang, Y. N., Gao, S., Lam, 
W. W., Chan, Y. L., and Kay, R. (1998). 
Intracranial stenosis in Chinese patients 
with acute stroke. Neurology 50, 812.
Zaidat, O. O., Klucznik, R., Alexander, M. 
J., Chaloupka, J., Lutsep, H., Barnwell, 
S., Mawad, M., Lane, B., Lynn, M. J., 
and Chimowitz, M. (2008). The NIH 
registry on the use of the Wingspan 
stent for symptomatic 70–99% intrac-
ranial arterial stenosis. Neurology 70, 
1518–1524.
Conflict of Interest Statement:  The 
authors declare that the research was con-
ducted in the absence of any commercial or 
financial relationships that could be con-
strued as a potential conflict of interest.
Received: 10 August 2010; accepted: 27 
December 2010; published online: 14 
February 2011.
Citation: Short JL, Majid A and Hussain 
SI (2011) Endovascular treatment of 
symptomatic intracranial atherosclerotic 
disease. Front. Neur. 1:160. doi: 10.3389/
fneur.2010.00160
This article was submitted to Frontiers in 
Endovascular and Interventional Neurology, 
a specialty of Frontiers in Neurology.
Copyright  ©  2011  Short,  Majid  and 
Hussain. This is an open-access article 
subject to an exclusive license agreement 
between the authors and Frontiers Media 
SA, which permits unrestricted use, distri-
bution, and reproduction in any medium, 
provided the original authors and source 
are credited.